Oragenics, Inc. OGEN
0.34 USD -0.01 (-3.30%)
At closeNov 10, 2026, 5:51 PM EST
0.36 +0.02 +4.93%
After hours · Nov 10, 5:51 PM ET
0.3431 Day range 0.358
0.34 52-week range 1.22
- YTD
- -56.01%
- 1 year
- -69.37%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
benzinga.com Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its…
benzinga.com Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.- benzinga.com Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San…
benzinga.com Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury • Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a…- benzinga.com Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002 Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
- benzinga.com Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has…
benzinga.com Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is…- benzinga.com Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has…
benzinga.com Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its…
benzinga.com Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design Oragenics, Inc. (NYSE American: OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced it has engaged…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket 
benzinga.com Reported November 7, 2025: Oragenics Q3 EPS $(1.96) Up From $(11.32) YoY Oragenics (AMEX:OGEN) reported quarterly losses of $(1.96) per share. This is a 82.69 percent increase over losses of $(11.32) per share from the same period last year.- benzinga.com Oragenics Regains Nasdaq Compliance Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has…
- benzinga.com Oragenics Selects Southern Star Research As Clinical Research Organization For Upcoming Phase IIa Clinical Trial Of ONP-002, Lead Drug Candidate For Concussion Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its…
- benzinga.com Oragenics Enters Manufacturing Agreement With Sterling Pharma For GMP Production Of Concussion Drug, ONP-002 Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June 
benzinga.com US Stocks Mixed; Dow Gains Over 50 Points - benzinga.com Oragenics Prices Public Offering Of Up To $20M Of Preferred Stock And Warrants Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Oragenics Receives Approval From HREC In Australia To Initiate Phase II Clinical Trial Evaluating ONP-002 For Treatment Of mTBI Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 89 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 116 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 72 companies hit new 52-week lows.